New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
08:21 EDTRHHBY, GSK, VVUS, OREX, ARNAU.S. market gets wave of new weight loss drugs, FT reports
The U.S. market has had only one prescription weight loss drug for several years, Roche’s (RHHBY) Xenical, which is also sold over-the-counter by GlaxoSmithKline (GSK) as Alli, but that drug has recently been joined by Vivus' (VVUS) Qsymia and Arena (ARNA) is set to launch Belviq shortly, reported Financial Times. Orexigen (OREX) is also preparing to re-submit its Contrave weight loss drug for a new regulatory review. The report on the resurgence of weight loss drug development noted that Vivus' CEO foresees the potential for using direct-to-consumer advertising and a larger scale sales force to market Qsymia, which would likely require a big pharma partner. Reference Link
News For VVUS;ARNA;OREX;GSK;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 22, 2015
18:28 EDTVVUSOn The Fly: After Hours Movers
Subscribe for More Information
16:15 EDTVVUSVIVUS initiated with an Outperform at RBC Capital
16:15 EDTOREXOrexigen initiated with an Outperform at RBC Capital
Subscribe for More Information
16:15 EDTARNAArena Pharmaceuticals initiated with a Sector Perform at RBC Capital
05:56 EDTARNAStocks with implied volatility below IV index mean; BBRY ARNA
Subscribe for More Information
January 21, 2015
12:30 EDTGSKGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
09:16 EDTARNAOn The Fly: Pre-market Movers
Subscribe for More Information
09:10 EDTARNAArena Pharmaceuticals 21M share Spot Secondary priced at $5.00
Subscribe for More Information
09:02 EDTRHHBYRoche's Ventana seeks FDA premarket approval for ALK IHC lung cancer assay
Roche Group member Ventana Medical Systems announced its FDA submission for premarket approval of the Ventana ALK CDx Assay. The companion diagnostic immunohistochemistry test is designed to identify ALK1-positive lung cancer patients that may benefit from treatment with targeted therapy that inhibits the ALK gene. This submission was the fourth and final module and application required by the FDA's PMA process.
08:51 EDTARNAArena Pharma sells 21M shares to Leucadia's Jefferies and Piper Jaffray
Arena Pharmaceuticals (ARNA) has sold 21M shares of common stock to Jefferies, a subsidiary of Leucadia (LUK) and to Piper Jaffray (PJC) as underwriters for its previously announced public offering. The offering is expected to close on or about January 26. In addition, Arena has granted the underwriters a 30-day option to purchase up to an aggregate of 3M additional shares of common stock. Arena anticipates using the net proceeds from the offering for the clinical and preclinical development of drug candidates, for discovery research for new drug candidates, and for general corporate purposes.
05:58 EDTARNAStocks with implied volatility below IV index mean; BBRY ARNA
Subscribe for More Information
January 20, 2015
18:30 EDTARNAOn The Fly: After Hours Movers
Subscribe for More Information
17:19 EDTARNAArena Pharmaceuticals cash, cash equivalents as of Dec. 31 $163.2M
Subscribe for More Information
16:05 EDTARNAArena Pharmaceuticals files to sell common stock, no amount given
Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.
09:10 EDTARNAArena sees Q4 Belviq sales down 35%-45% vs. Q3
Subscribe for More Information
06:08 EDTARNAStocks with implied volatility below IV index mean; BBRY ARNA
Subscribe for More Information
January 16, 2015
16:36 EDTRHHBYMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
08:31 EDTGSKGlaxoSmithKline CEO says more IPOs like ViiV could happen, Retuers says
Subscribe for More Information
06:21 EDTRHHBYRoche acquires Trophos for EUR120M plus contingent payments
Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos’s proprietary screening platform generated olesoxime, TRO19622, which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a pivotal phase II clinical trial with olesoxime in SMA showed a beneficial effect on the maintenance of neuromuscular function in individuals with Type II and non-ambulatory Type III SMA, as well as a reduction in medical complications associated with the disease. These data were first presented in April 2014 at the annual meeting of the American Academy of Neurology. Under the terms of the agreement, Trophos’s shareholders will receive an upfront cash payment of EUR 120M, plus additional contingent payments of up to EUR 350M based on achievement of certain predetermined milestones.
06:10 EDTARNAStocks with implied volatility below IV index mean; BBRY ARNA
Stocks with implied volatility below IV index mean; BlackBerry (BBRY) 63, Arena Pharmaceuticals (ARNA) 86 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use